Oegstgeest, The Netherlands, 24 October 2023 – ISA is pleased to announce that it will be presenting during the 4th Annual H.C. Wainwright Virtual HBV Conference – October 25th. The presentation by Gerben Moolhuizen, CEO of ISA Pharmaceuticals, will highlight key characteristics and progress in the development of ISA104, a therapeutic vaccine aimed to aid in achieving functional cure of patients suffering from chronic hepatitis B infection.
Presentation title: Targeted Immune System Activation using SLPs in chronic HBV
Time: 5:00 – 5:30pm CET
ISA104 immunotherapy has been designed to create a strong and specific immune response against HBV, with the aim to achieve functional cure in chronically infected patients. ISA Pharmaceuticals has previously demonstrated the effectiveness of SLP immunotherapy in patients that were chronically infected with human papillomavirus type 16 (HPV16). ISA104 entered clinical development in August of this year.
Hepatitis B is a serious liver infection and a global health threat caused by the development of chronic infection in a proportion of patients who are unable to clear the virus and become carriers. Two billion people around the world have been infected with the hepatitis B virus, with approximately 1.5 million people becoming newly infected each year. Approximately 300 million people are suffering from the chronic sequelae of this disease.
ISA’s versatile synthetic long peptide (SLP®) immunotherapy platform is yielding multiple, highly promising clinical stage immunotherapeutics for the treatment of different cancer types and infectious diseases. It has demonstrated to be best-in-class technology to strongly and specifically activate the human immune system. SLP immunotherapeutics have been tested in multiple human clinical proof-of-concept and phase 2 trials, both as monotherapies and in combination with checkpoint inhibitors or standard-of-care chemotherapy.